Skip to main content
NCBI home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1996 Aug;49(4):M203–M208. doi: 10.1136/mp.49.4.m203

Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours

B Terris 1,2,3,4,5,6, J F Fléjou 1,2,3,4,5,6, S Dubois 1,2,3,4,5,6, P Ruszniewski 1,2,3,4,5,6, J Y Scoazec 1,2,3,4,5,6, J Belghiti 1,2,3,4,5,6, F Potet 1,2,3,4,5,6, P Bernades 1,2,3,4,5,6, M Mignon 1,2,3,4,5,6, D Hénin 1,2,3,4,5,6
PMCID: PMC408059  PMID: 16696075

Abstract

Aims/background—To analyse the different isoforms of CD44 in various types of endocrine pancreatic and gut carcinoid tumours and to investigate the relation between their expression and tumour dissemination. This study was prompted by the recent observation that inappropriate splicing of the CD44 gene was correlated with tumour progression and metastasis formation in a number of human cancers.

Methods—Expression of CD44 isoforms was studied in 38 endocrine pancreatic tumours and gut neuroendocrine tumours using antibodies directed against products of exons v3, v4-v5, v6, v7-v8 as well as against the standard CD44 molecule (CD44H). CD44 gene expression was also analysed by reverse transcription PCR (RT-PCR) in nine endocrine and seven carcinoid tumours.

Results—All gastrinomas except one (nine of 10) and about half of the other endocrine pancreatic tumours (seven of 15) expressed CD44v6. Most (10/11) midgut carcinoid tumours were CD44v6 negative, with no detectable immunostaining. CD44v3, CD44v4-v5 and CD44v7-v8 were not expressed in any of these tumours. CD44 mRNA analysis illustrated a complex splice pattern and expression of large CD44 isoforms in CD44v6 positive endocrine tumours, whereas the standard form only was detected in midgut carcinoid tumours. No correlation between CD44 variant expression and tumour metastasis was observed.

Conclusions—CD44 variants encoding exon v6 are preferentially expressed both in gastrinomas and in most pancreatic endocrine tumours. In contrast to other tumours, the expression of CD44v6 in pancreatic neuroendocrine tumours does not seem to be correlated with tumour dissemination.

Keywords: pancreas

Keywords: neuroendocrine tumours

Keywords: CD44

Keywords: alternative splicing

Full text

PDF
M203

Images in this article

M205Image
on p.M205
M206Image
on p.M206
M207Image
on p.M207

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cannistra S. A., Kansas G. S., Niloff J., DeFranzo B., Kim Y., Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993 Aug 15;53(16):3830–3838. [PubMed] [Google Scholar]
  2. Chaudhry A., Gobl A., Eriksson B., Skogseid B., Oberg K. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res. 1994 Feb 15;54(4):981–986. [PubMed] [Google Scholar]
  3. Dall P., Heider K. H., Sinn H. P., Skroch-Angel P., Adolf G., Kaufmann M., Herrlich P., Ponta H. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer. 1995 Feb 8;60(4):471–477. doi: 10.1002/ijc.2910600408. [DOI] [PubMed] [Google Scholar]
  4. Fox S. B., Fawcett J., Jackson D. G., Collins I., Gatter K. C., Harris A. L., Gearing A., Simmons D. L. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994 Aug 15;54(16):4539–4546. [PubMed] [Google Scholar]
  5. Fujita N., Yaegashi N., Ide Y., Sato S., Nakamura M., Ishiwata I., Yajima A. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res. 1994 Jul 15;54(14):3922–3928. [PubMed] [Google Scholar]
  6. Graham R. C., Jr, Karnovsky M. J. The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem. 1966 Apr;14(4):291–302. doi: 10.1177/14.4.291. [DOI] [PubMed] [Google Scholar]
  7. Günthert U., Hofmann M., Rudy W., Reber S., Zöller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991 Apr 5;65(1):13–24. doi: 10.1016/0092-8674(91)90403-l. [DOI] [PubMed] [Google Scholar]
  8. Harn H. J., Ho L. I., Chang J. Y., Wu C. W., Jiang S. Y., Lee H. S., Lee W. H. Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer. 1995 Mar 1;75(5):1065–1071. doi: 10.1002/1097-0142(19950301)75:5<1065::aid-cncr2820750503>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  9. Heider K. H., Hofmann M., Hors E., van den Berg F., Ponta H., Herrlich P., Pals S. T. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol. 1993 Jan;120(1):227–233. doi: 10.1083/jcb.120.1.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Iida N., Bourguignon L. Y. New CD44 splice variants associated with human breast cancers. J Cell Physiol. 1995 Jan;162(1):127–133. doi: 10.1002/jcp.1041620115. [DOI] [PubMed] [Google Scholar]
  11. Kaufmann M., Heider K. H., Sinn H. P., von Minckwitz G., Ponta H., Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet. 1995 Mar 11;345(8950):615–619. doi: 10.1016/s0140-6736(95)90521-9. [DOI] [PubMed] [Google Scholar]
  12. Kenny B. D., Sloan J. M., Hamilton P. W., Watt P. C., Johnston C. F., Buchanan K. D. The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer. 1989 Jul 15;64(2):460–465. doi: 10.1002/1097-0142(19890715)64:2<460::aid-cncr2820640220>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  13. Klöppel G., Heitz P. U. Pancreatic endocrine tumors. Pathol Res Pract. 1988 Apr;183(2):155–168. doi: 10.1016/S0344-0338(88)80043-8. [DOI] [PubMed] [Google Scholar]
  14. Koopman G., Heider K. H., Horst E., Adolf G. R., van den Berg F., Ponta H., Herrlich P., Pals S. T. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med. 1993 Apr 1;177(4):897–904. doi: 10.1084/jem.177.4.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mason D. Y., Sammons R. E. The labeled antigen method of immunoenzymatic staining. J Histochem Cytochem. 1979 Apr;27(4):832–840. doi: 10.1177/27.4.109496. [DOI] [PubMed] [Google Scholar]
  16. Matsumura Y., Sugiyama M., Matsumura S., Hayle A. J., Robinson P., Smith J. C., Tarin D. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol. 1995 Sep;177(1):11–20. doi: 10.1002/path.1711770104. [DOI] [PubMed] [Google Scholar]
  17. Matsumura Y., Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992 Oct 31;340(8827):1053–1058. doi: 10.1016/0140-6736(92)93077-z. [DOI] [PubMed] [Google Scholar]
  18. Mayer B., Jauch K. W., Günthert U., Figdor C. G., Schildberg F. W., Funke I., Johnson J. P. De-novo expression of CD44 and survival in gastric cancer. Lancet. 1993 Oct 23;342(8878):1019–1022. doi: 10.1016/0140-6736(93)92879-x. [DOI] [PubMed] [Google Scholar]
  19. Metz D. C., Kuchnio M., Fraker D. L., Venzon D. J., Jaffe G., Jensen R. T., Stetler-Stevenson M. Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology. 1993 Sep;105(3):799–813. doi: 10.1016/0016-5085(93)90898-m. [DOI] [PubMed] [Google Scholar]
  20. Mulder J. W., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., Weidema W. F., Offerhaus G. J., Pals S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1994 Nov 26;344(8935):1470–1472. doi: 10.1016/s0140-6736(94)90290-9. [DOI] [PubMed] [Google Scholar]
  21. Mulder J. W., Wielenga V. J., Polak M. M., van den Berg F. M., Adolf G. R., Herrlich P., Pals S. T., Offerhaus G. J. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut. 1995 Jan;36(1):76–80. doi: 10.1136/gut.36.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pelosi G., Zamboni G., Doglioni C., Rodella S., Bresaola E., Iacono C., Serio G., Iannucci A., Scarpa A. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am J Surg Pathol. 1992 Dec;16(12):1215–1225. doi: 10.1097/00000478-199212000-00008. [DOI] [PubMed] [Google Scholar]
  23. Penno M. B., August J. T., Baylin S. B., Mabry M., Linnoila R. I., Lee V. S., Croteau D., Yang X. L., Rosada C. Expression of CD44 in human lung tumors. Cancer Res. 1994 Mar 1;54(5):1381–1387. [PubMed] [Google Scholar]
  24. Seiter S., Arch R., Reber S., Komitowski D., Hofmann M., Ponta H., Herrlich P., Matzku S., Zöller M. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993 Feb 1;177(2):443–455. doi: 10.1084/jem.177.2.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sy M. S., Guo Y. J., Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med. 1991 Oct 1;174(4):859–866. doi: 10.1084/jem.174.4.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tanabe K. K., Ellis L. M., Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993 Mar 20;341(8847):725–726. doi: 10.1016/0140-6736(93)90490-8. [DOI] [PubMed] [Google Scholar]
  27. Terpe H. J., Koopmann R., Imhof B. A., Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol. 1994 Oct;174(2):89–100. doi: 10.1002/path.1711740205. [DOI] [PubMed] [Google Scholar]
  28. Thomas L., Byers H. R., Vink J., Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 1992 Aug;118(4):971–977. doi: 10.1083/jcb.118.4.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Washington K., Gottfried M. R., Telen M. J. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol. 1994 Oct;25(10):1043–1049. doi: 10.1016/0046-8177(94)90063-9. [DOI] [PubMed] [Google Scholar]
  30. von Herbay A., Sieg B., Schürmann G., Hofmann W. J., Betzler M., Otto H. F. Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut. 1991 Aug;32(8):949–953. doi: 10.1136/gut.32.8.949. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES